Danish Covid-19 therapy shows promise in phase I trial

Union Therapeutics' study with the drug niclosamide for treating Covid-19 patients with kidney diseases shows promising data in a Danish phase I trial program.
Photo: Union Therapeutics / PR
Photo: Union Therapeutics / PR

Biotech company Union Therapeutics is excited about positive preliminary trial data involving the company's niclosamide nasal spray, which it hopes will have an efficient impact on kidney patients with Covid-19.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading